E-Mail to a Friend

Dr. Edward Libby at ASH 2013

Dr. Edward Libby provides an update on multiple myeloma treatment at ASH 2013. Dr. Libby is most excited about the research that's going into monoclonal antibodies for treatment of multiple myeloma. Monoclonal antibodies are relatively non-toxic, but have added to the quality of response in treatment of other diseases such as lymphoma. New trials are being conducted with Daratumumab in combination with Revlimid and Dexamethasone, with remarkable results for patients with relapsed and refractory multiple myeloma. Our understanding of smoldering myeloma is rapidly increasing, and positive results have been seen from beginning treatment at this earlier stage. However, Dr. Libby cautions that there is still much to learn and treatment of smoldering myeloma is not ready for the general world of oncology.

Related Videos

Treating Multiple Myeloma with Bisphosphonates

In this video from our ""Living Well With Multiple Myeloma"" event held at SCCA in November 2011, Dr. Noopur Raje discusses treating myeloma with bisphosphonates with Andrew Schorr from Patient Power. Dr. Noopur Raje advocates the use of bisphosphonates in treating symptomatic myeloma, and explains how they work on the accessory cells which surround myeloma cells. She discusses the side effects related to the toxicities of bisphosphonates such as osteonecrosis of the jaw (ONJ). Current guidelines suggest bisphosphonates treatment for up to two years. Dr. Raje will be releasing data from a recent study supporting reducing the frequency of bisphosphonates treatments to every three months.

Multiple Myeloma Treatment and Research

In this video from our ""Living Well With Multiple Myeloma"" event held at SCCA in November 2011, Drs. William Bensinger of Seattle Cancer Care Alliance, and Noopur Raje of Massachusetts General Hospital discuss treatment and research for multiple myeloma with Andrew Schorr from Patient Power. Dr. Raje, who researches drugs that can help with the bone complications of myeloma, states that they are able to decrease the risk of fractures by about 50% with bisphosphonates. She also discusses a clinical trial which uses osteoblasts to promote bone healing. In the more than 20 years that Dr. Bensinger has studied myeloma, he has never been more hopeful about his ability to fight the disease. Proteasome inhibitors such as bortezomib have dramatically changed the landscape. Remissions have lasted longer and patients have lived longer as a result of these drugs. Learn more about advancements in treatment of myeloma.

Multiple Myeloma Testing and Personalized Treatment

In this video from our ""Living Well With Multiple Myeloma"" event held at SCCA in November 2011, Drs. William Bensinger and Dr. Noopur Raje discuss testing for the treatment of myeloma with Andrew Schorr from Patient Power. With the heterogeneity of the disease, adjusting the drug schedule and combination for the individual patient is the key to treatment efficacy and the control of side effects. Dr. Raje describes the panel of tests used to determine the appropriate individualized treatment regimen.